About Migranal

MIGRANAL® (dihydroergotamine mesylate, USP) Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura. MIGRANAL has the ability to relieve moderate to severe migraine pain — long after a migraine has started.

Learn more about what MIGRANAL offers your migraine patients:

  • Why Patients Wait In a recent study, 85% of patients did not treat their migraine until it was moderate or severe.
     
  • Efficacy MIGRANAL offers rapid relief of moderate to severe migraine pain.
     
  • Long-lasting Relief MIGRANAL provides long lasting relief and a low recurrence rate.
     
  • Mechanism of Action MIGRANAL offers broad receptor coverage at multiple receptor sites but is less-receptor specific, allowing it to work anytime during a migraine.
     
  • Distinguishing Features of DHE The active ingredient in MIGRANAL — DHE — has been in use in patients with migraines for more than 50 years and works on both peripheral and central migraine pain components.
     
  • Redesigned Delivery System Redesigned MIGRANAL is simple and easy for patients to use.

Next page: Why Patients Wait

IMPORTANT SAFETY INFORMATION:

Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.

MIGRANAL Nasal Spray should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm, including Prinzmetal's variant angina. MIGRANAL also should not be given to patients with uncontrolled hypertension, patients who have used 5-HT1 agonists, ergotamine-containing or ergot-type medications or methysergide within the last 24 hours, or patients with hemiplegic or basilar migraine. MIGRANAL Nasal Spray is also contraindicated in patients with known peripheral arterial disease, sepsis, following vascular surgery, and severely impaired hepatic or renal function. MIGRANAL Nasal Spray should not be administered in pregnant women or nursing mothers.

Serious cardiac events, including some that have been fatal, have occurred following use of DHE 45 but are extremely rare. During clinical studies and the foreign post-marketing experience with MIGRANAL Nasal Spray, there have been no fatalities due to cardiac events.

The most commonly reported adverse events in clinical trials for MIGRANAL Nasal Spray were rhinitis, altered sense of taste, application site reactions, dizziness, nausea, and vomiting. Adverse events associated with discontinuation were rhinitis, dizziness, facial edema, cold sweats, accidental trauma, depression, elective surgery, somnolence, allergy, vomiting, hypotension, and paresthesia.

Please see accompanying complete prescribing information including BOXED warning.

Home | About Migranal | Optimize Migraine Treatment | Professional Resources
Prescribing Information | Site Map | Privacy and Legal Statement | Contact Us